What to verify: Laboratory name and accreditation status indicate testing credibility
Last reviewed: July 17, 2026 Last updated: July 17, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Available from: Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA (2017) Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
On April 30, 2026, the FDA took the more sweeping step of proposing to permanently exclude semaglutide, tirzepatide and liraglutide from the 503B Bulks List the list of ingredients that large-scale compounding facilities are legally permitted to use